Eli Lilly: Xigris (A) Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

Xigris development and launch costs: $250M (Para 14).
Projected peak annual sales: $1B to $2B (Para 15).
Price per treatment course: $6,800 (Para 18).
Cost of goods sold (COGS): Low, as Xigris is a protein-based biologic (Para 19).
Company R&D budget: $2.3B annually (Para 22).

Operational Facts

Product: Recombinant human activated protein C (rhAPC), the first treatment for severe sepsis (Para 1).
Regulatory status: FDA approval received in November 2001 (Para 17).
Target market: ICU patients with severe sepsis and organ dysfunction (Para 2).
Manufacturing: Complex biologic production; potential for capacity constraints (Para 20).
Distribution: Requires intensive hospital-based sales force (Para 21).

Stakeholder Positions

Lilly Management: High confidence in medical breakthrough; pressure to recoup $250M investment (Para 14).
FDA: Approved with a black box warning due to bleeding risks (Para 17).
Hospital Pharmacy Committees: Concerned about the $6,800 price tag relative to hospital budgets (Para 18).

Information Gaps

Specific adoption rates in the first 90 days post-launch.
Competitor responses (e.g., alternative sepsis treatments in pipeline).
Actual hospital mortality reduction vs. clinical trial data in real-world settings.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

How should Eli Lilly price and position Xigris to ensure rapid hospital adoption while navigating high price sensitivity and significant clinical safety concerns?

Structural Analysis

Value Chain: The drug requires high-touch clinical education. The barrier is not just the drug efficacy but the hospital protocol integration.
Porter Five Forces: Buyer power is high; hospital pharmacy and therapeutics committees act as gatekeepers. The threat of substitutes is currently low, as Xigris is the first FDA-approved treatment for severe sepsis.

Strategic Options

Option 1: Value-Based Pricing (High entry price). Maintain $6,800 price point, focusing on the reduction of ICU days. Trade-off: High risk of formulary rejection.
Option 2: Tiered Access/Clinical Partnership. Lower the price for high-volume hospitals in exchange for long-term data collection. Trade-off: Complexity in administration and potential price erosion.
Option 3: Aggressive Clinical Education. Maintain price but shift budget from promotion to clinical support teams (medical science liaisons). Trade-off: Higher operating expenses, delayed profitability.

Preliminary Recommendation

Pursue Option 3. The complexity of sepsis diagnosis and the bleeding risk profile necessitate deep clinical engagement rather than mass-market promotion.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

Deploy 200 dedicated Medical Science Liaisons (MSLs) to top 500 US hospitals within 60 days.
Establish a real-time registry to track patient outcomes and adverse events (bleeding).
Secure formulary approval at the top 100 teaching hospitals by month 6.

Key Constraints

Diagnosis Latency: Physicians must identify severe sepsis early for Xigris to be effective.
Safety Perception: The black box warning on bleeding risk creates immediate hesitation among intensivist staff.

Risk-Adjusted Implementation

Allocate 15% of the marketing budget to a contingency fund for additional safety studies if early post-market data shows higher-than-expected bleeding events.

4. Executive Review and BLUF (Executive Critic)

BLUF

Lilly is attempting to market a complex biologic with severe safety risks into a fragmented, budget-constrained hospital environment. The $6,800 price tag is secondary to the lack of a standardized diagnostic protocol for severe sepsis. If Lilly does not shift from a pharmaceutical sales model to a clinical protocol partnership model, Xigris will fail to achieve the required penetration. The current strategy assumes physicians will prioritize mortality reduction over budget and liability management; this is a fatal error. Lilly must lead the creation of a sepsis-management protocol, not just sell a drug.

Dangerous Assumption

The assumption that intensive care physicians will independently adopt Xigris based on clinical trial efficacy data without a systemic shift in hospital diagnostic protocols.

Unaddressed Risks

Legal Liability: If the black box warning leads to litigation, the $250M investment is at risk of total write-down. (High Probability, High Consequence).
Payor Pushback: CMS and private insurers may refuse reimbursement if the cost-benefit analysis of 28-day survival is not clearly demonstrated in real-world data. (Medium Probability, High Consequence).

Unconsidered Alternative

Outsource the clinical education component to a third-party critical care organization to distance Lilly from the direct promotion of a drug with significant safety warnings.